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Review

Gasdermins in Apoptosis: New players in an
Old Game
Corey Rogers and Emad S. Alnemri*
Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia,
PA

Apoptosis is a form of programmed cell death (PCD†) that plays critical physiological roles in removing
superfluous or dangerous cell populations that are unneeded or threatening to the health of the host
organism. Although the molecular pathways leading to activation of the apoptotic program have been
extensively studied and characterized starting in the 1970s, new evidence suggests that members of the
gasdermin superfamily are novel pore-forming proteins that augment apoptosis by permeabilizing the
mitochondria and participate in the final stages of the apoptotic program by inducing secondary necrosis/
pyroptosis. These findings may explain outstanding questions in the field such as why certain gasdermin
members sensitize cells to apoptosis, and why some apoptotic cells also show morphological features of
necrosis. Furthermore, the interplay between the gasdermins and apoptosis may also explain why genetic
and epigenetic alterations in these genes cause diseases and disorders like cancer and hearing loss. This
review focuses on our current understanding of the function of several gasdermin superfamily members,
their role in apoptosis, and how they may contribute to pathophysiological conditions.

INTRODUCTION
Apoptosis is a genetically encoded form of programmed cell death (PCD) that is carried out by programmed molecular machinery and plays a variety of
vitally important physiological roles in organismal development and homeostasis (Table 1). In humans, a coordinated series of complex cellular signaling events results
in the transformation of a single-cell zygote to a fully
mature adult composed of trillions of cells that make up
very specialized organs. While mitosis results in the proliferation of cells that eventually composes these organs,
it is actually apoptosis that fine-tunes their structure, re-

sulting in the final form and function they eventually take.
Apoptosis also plays important functions in eliminating
transformed or pathogen-infected cells that are deleterious to the host. Apoptosis can be triggered intrinsically
when cells sense their own irreparable cellular damage
(e.g. DNA damage) and stress, or extrinsically through
activation of death receptors on the plasma membrane by
death-inducing cytokines released from cells as a result
of infection with pathogens (Figure 1). Intrinsic apoptosis is triggered by signaling pathways controlled largely
by members of the proapoptotic B Cell CLL/Lymphoma-2 (BCL-2) family which ultimately culminate on the
BCL-2 effectors, BCL-2 Antagonist Killer 1 (BAK), and
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Table 1. Cell death definitions.
Term

Definition

Programmed Cell
Death (PCD)

Cell death that is regulated by genetically encoded molecules in response to physiological
or pathophysiological stimuli

Apoptosis

An immunologically silent form of PCD driven by the executioner caspases that typically
results in rapid engulfment by nearby phagocytes

Pyroptosis

An immunogenic form of PCD driven by the inflammatory caspase-mediated cleavage of
GSDMD in response to pathogen- and danger- associated molecular patterns (PAMPs and
DAMPs, respectively)

Secondary Necrosis

An immunogenic form of PCD driven by the caspase-3-mediated cleavage of GSDME that
can sometimes follow the apoptotic program; secondary necrotic cells display very similar
features to those undergoing pyroptosis

NETosis

An immunogenic form of PCD occurring specifically in neutrophils driven by the
inflammatory caspase-mediated cleavage of GSDMD, resulting in the release of neutrophil
extracellular traps (NETs)

Figure 1. Features of cells undergoing apoptosis, pyroptosis or secondary necrosis. Apoptosis is orchestrated by
the executioner caspases 3 and 7 which are activated by the apoptosome or death receptor ligation. Cells undergoing
apoptosis are characterized by their defining blebs around the plasma membrane, cellular shrinkage, fragmentation
into apoptotic bodies, nuclear condensation, and mitochondrial outer membrane permeabilization. Pyroptosis
is orchestrated by cleavage of GSDMD by inflammatory caspases 1 and 11 within the inflammasome complexes,
whereas secondary necrosis is orchestrated by cleavage of GSDME by caspase-3 during apoptosis. Cells undergoing
pyroptosis/secondary necrosis exhibit permeabilized plasma and organelle membranes, cellular swelling, and release
of intracellular contents through the GSDMD or GSDME pores. These cells, unlike apoptotic cells, do not maintain their
plasma membrane integrity.
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BCL-2-Associated X Protein (BAX). Activation of these
proteins leads to their oligomerization on the outer mitochondrial membrane resulting in its permeabilization and
the release of proapoptotic factors such as cytochrome c.
The released cytochrome c activates the Apaf-1 apoptosome which in turn activates the executioner caspases 3
and 7 leading to cellular dismantling [1-5]. While BAK
and BAX have been the most extensively characterized
apoptotic mitochondrial pore-forming proteins, recent
evidence demonstrates that members of the gasdermin
superfamily also possess similar functions.
The gasdermin superfamily is a group of proteins
that has garnered much attention lately upon the discovery that these members possess the ability to form pores
in the plasma membrane leading to a necrotic form of
programmed cell death called pyroptosis (Table 1; Figure
1). This novel function was first discovered in gasdermin
D (GSDMD) when it was shown that cleavage between
the N- and C-terminal domains by the inflammatory
caspases such as caspase-1 and caspase-11 liberates a
cytotoxic N-terminus [6-8] that oligomerizes and permeabilizes the plasma membrane to drive pyroptosis [9-14].
Subsequently, it was identified that another member of
the superfamily, GSDME, is also cleaved between its Nand C-terminal domains by caspase-3 during apoptosis
which, similar to GSDMD, also liberates a cytotoxic
N-terminus that permeabilizes the plasma membrane and
may drive secondary necrosis (Table 1; Figure 1) [15,16].
Furthermore, this N-terminal pore-forming function is
conserved in all superfamily members, except DFNB59,
although the mechanism of activation of other members
currently remains unknown [14]. Interestingly, recent
evidence suggests that in addition to forming pores in the
plasma membrane, this family also possesses the ability to form pores in mitochondrial membranes which is
important in augmenting the apoptotic response and may
serve to bridge activation of the pyroptotic pathway to the
apoptotic pathway [17].
APOPTOSIS
Intrinsic Apoptotic Pathway
Mechanistically, apoptosis can be activated by one
of two pathways: the intrinsic or the extrinsic apoptotic
pathway. Activation of the intrinsic apoptotic pathway
arises when cells sense intracellular or extracellular
stresses such as DNA damage, viral or bacterial infection, growth factor withdrawal, glucocorticoids, ROS
overload, or hypoxia. These stimuli begin a cascade of
signaling by the pro-apoptotic BCL-2 family members
whose expression and activation ultimately leads to disruption of mitochondrial function via mitochondrial outer
membrane permeabilization (MOMP) [1,18-22].
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All BCL-2 family members share one to four BCL2 homology (BH) domains and are divided into three
groups: the proapoptotic effectors, the antiapoptotic
BCL-2-like members, and the proapoptotic BH3-only
members [2]. The proapoptotic effectors include BAK,
BAX, and BCL-2-related ovarian killer (BOK) which are
unique in their ability to oligomerize and directly form
pores in the outer mitochondrial membrane (OMM) leading to MOMP and the release of additional proapoptotic
factors that potentiate apoptotic signaling [1-5]. While
BAX cycles between the cytosol and the OMM and BAK
permanently localizes to the OMM, both are inhibited
from forming mitochondrial pores by the activity of the
antiapoptotic BCL-2 family members [23-25]. These
members include BCL-2, BCL-w, BCL-2-related gene,
long isoform (BCL-xL), myeloid cell leukemia 1 (MCL1), and BCL-2 related protein A1 (A1 or BFL-1) which
reside predominantly in the OMM and function to antagonize the proapoptotic BCL-2 family members by directly binding to and sequestering them [26-29]. Binding
of antiapoptotic BCL-2 family members to proapoptotic
effectors prevents their ability to form oligomers in the
OMM and can also promote their retrotranslocation away
from the OMM to the cytosol [1,2,25]. Furthermore, antiapoptotic BCL-2 family members can block apoptosis
by sequestering proapoptotic BH3-only members that
directly activate BAK and BAX (Figure 2) [5,30,31].
To overcome the inhibitory effects of the antiapoptotic BCL-2 members, the proapoptotic BH3-only
members which include BCL-2 antagonist of cell death
(BAD), BCL-2 modifying factor (BMF), harakiri (HRK),
p53-upregulated modulator of apoptosis (PUMA),
BCL-2-interacting killer (BIK), NOXA, BCL-2-interacting mediator of cell death (BIM), and BCL-2-interacting
domain death agonist (BID) are activated in response to
cellular stresses or developmental cues. Activation occurs
transcriptionally such as with the p53-mediated upregulation of PUMA or post-translationally such as with the
caspase-8-medited proteolytic cleavage of BID [32-35].
Some proapoptotic BH3-only members (i.e. BID, BIM,
PUMA, and NOXA) directly activate the intrinsic apoptotic pathway by binding to BAK and BAX leading to
a conformational change that allows for their oligomerization in the OMM [36-38] while other members (i.e.
BAD, BMF, HRK) can promote apoptosis indirectly by
binding to and inhibiting the antiapoptotic BCL-2 family
members from sequestering BAK and BAX [39-41].
Once BAK and BAX induce MOMP, proapoptotic
factors including Cytochrome c (Cyt c), High Temperature Requirement Protein A2 (HtrA2/Omi), and second
mitochondrial activator of caspases/direct IAP-binding
protein with low pI (Smac/DIABLO) are released from
the mitochondria into the cytosol where they continue
the apoptotic signaling cascade [42-45]. HtrA2/Omi and
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Figure 2. Intrinsic and extrinsic apoptotic activation. Activation of the apoptotic program can occur intrinsically
when cells sense internal damage and stress leading to activation of the proapoptotic BH3-only BCL-2 family members.
The BH3-only proteins prevent anti-apoptotic BCL-2-like proteins from inhibiting Bak/Bax oligomerization on the OMM.
Once oligomerized, proapoptotic factors like Cyt c escape into the cytosol and activate caspase-3 via the Apaf-1
apoptosome. Extrinsic apoptotic activation occurs when death ligands bind to cell surface death receptors leading
to the recruitment and activation of pro-caspase-8. Active caspase-8 can then directly activate caspase-3 to begin
dismantling the cell or cleave BID to activate the intrinsic apoptotic pathway.

Smac/DIABLO function by binding to and inactivating
the inhibitors of apoptosis (IAPs) which normally bind
to and inhibit activation of the caspases [43,46-49]. In
addition, Cyt c binds to the cytosolic adaptor molecule
apoptotic protease activating factor 1 (Apaf-1) leading
to a conformational change that results in its oligomerization, formation of the apoptosome, and recruitment of
the initiator caspase pro-caspase-9 [50,51]. Pro-caspase-9
autoproteolytically processes itself generating a fully active caspase-9 protease which then cleaves the effector
caspases pro-caspase-3, -6, and -7 leading to their fully active proteolytic forms [51]. These caspases target
hundreds of cellular substrates for proteolysis, leading
to the characteristic morphological changes associated
with cells undergoing apoptosis such as DNA fragmentation, plasma membrane blebbing, cell shrinkage, and
the flipping of phosphatidylserine from the inner plasma
membrane leaflet to the outer (Figures 1 and 2) [52-56].
Extrinsic Apoptotic Pathway
While the outcome of extrinsic and intrinsic apoptotic signaling is virtually identical, these pathways differ in
their mode of activation. In contrast to the intrinsic apoptotic pathway, activation of the extrinsic apoptotic pathway occurs via the extracellular binding of ligands such
as Fas ligand (FasL), tumor necrosis factor (TNF) α, and
TNF-Related Apoptosis-Inducing Ligand (TRAIL) to the
cell surface death receptors Fas (CD95 or APO-1), TNF
receptor superfamily member 1A (TNFR1), and TRAIL

receptor 1 (TRAILR1), respectively. Binding of these ligands to their receptors induces conformational changes
in the intracellular trimerized receptor tails that allows for
the recruitment of adaptor molecules like Fas associated
death domain (FADD) protein to Fas and TRAILR1 or
TNFR1 associated death domain (TRADD) protein to
TNFR1 [57-63]. The initiator caspase pro-caspase-8 is
then directly recruited to FADD via homotypic death effector domain (DED) interactions or indirectly recruited
to TRADD via FADD-TRADD interactions leading to
pro-caspase-8 dimerization and subsequent autoproteolytic activation [63-65]. Of note, TNFα-mediated apoptosis can be dependent or independent on the kinase activity
of the serine/threonine kinase receptor-interacting protein
kinase 1 (RIPK1) depending on RIPK1 phosphorylation
status [66] . Once activated, caspase-8 cleaves and activates pro-caspase-3 which carries out the dismantling of
the cellular machinery as outlined above [67,68].
Intriguingly, activation of the extrinsic apoptotic
pathway can lead to activation of the intrinsic apoptotic pathway via the proapoptotic BH3-only member
BID. BID is normally found inactive in the cytosol but
is cleaved by caspase-8 generating an active C-terminal
fragment called truncated BID (tBID) [32-34]. tBID translocates to the mitochondria where it binds to and directly
activates oligomerization of BAX/BAK pores leading to
MOMP and activation of the Apaf-1 apoptosome (Figure
2) [37,38]. It is interesting to note, however, that genetic
knockout or knockdown of BID only partially reduces
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Figure 3. GSDMD-mediated pyroptosis. Macrophages and dendritic cells sensing DAMPs and PAMPs will activate
canonical inflammasome assemblies leading to the recruitment and activation of procaspase-1 (procasp-1). Intracellular
LPS from gram-negative bacteria binds to and activates procaspases -4 or -5 (-11 in mice; procasp-4, -5, -11) forming
the noncanonical inflammasome. Active inflammatory caspases cleave GSDMD liberating an ~30 kDa N-terminal
fragment (GSDMD-N) that translocates and oligomerizes to form pores in the plasma membrane. These pores allow
the release of proinflammatory molecules like HMGB1, IL-1β, and IL-18 and disrupt ionic gradients leading to cellular
swelling and pyroptosis. GSDMD-N also permeabilizes the mitochondria, releasing proapoptotic factors like Cyt c
leading to activation of caspase-3 via the Apaf-1 apoptosome.

Figure 4. GSDME-N permeabilizes the plasma and mitochondrial membranes. Activation of the intrinsic apoptotic
pathway by glucocorticoids, UV irradiation, etoposide, or serum starvation or the extrinsic apoptotic pathway by TNFα
leads to activation of caspase-3. Active caspase-3 cleaves GSDME generating a pore-forming (GSDME-N) ~30 kDa
N-terminal fragment that translocates to and permeabilizes the mitochondria. Proapoptotic factors are released through
GSDME-N mitochondrial pores and positively feedback on caspase-3 activation and GSDME cleavage (green arrows).
After mitochondrial permeabilization, GSDME-N forms pores in the plasma membrane leading to secondary necrosis/
pyroptosis, which allows the release of proinflammatory DAMP molecules like HMGB1.
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the magnitude and delays the kinetics of Cyt c release,
caspase-3 activation, and cell death in mouse hepatocytes
and human islet cells treated with TNFα or FasL, respectively, suggesting the possibility of other molecules that
can bridge activation of the extrinsic apoptotic pathway
to that of the intrinsic [69,70]. Indeed, it was recently
demonstrated that similar to BID, GSDME is cleaved
downstream of the extrinsic apoptotic pathway and that
the active fragment, GSDME-N, independently induces
the release of Cyt c from the mitochondria to promote
caspase-3 activation [17].
The Gasdermin Superfamily
Humans encode six gasdermin superfamily members including GSDMA, GSDMB, GSDMC, GSDMD,
GSDME/DFNA5, and DFNB59 while mice encode ten
including three GSDMA orthologs (Gsdma1, Gsdma2,
and Gsdma3), four GSDMC orthologs (Gsdmc1, Gsdmc2, Gsdmc3, and Gsdmc4), Gsdmd, Gsdme/Dfna5, and
Dfnb59, but no GSDMB orthologs. All members share
~45% sequence homology and, except for DFNB59,
adopt a two-domain architecture characterized by globular N- and C-terminal domains separated by a flexible
linker region [7,14]. The N-terminal domains (GSDM-N)
of all members except DFNB59 can oligomerize and
form membrane-spanning pores in the plasma membrane
resulting in the disruption of ionic gradients, osmotic
cellular swelling, and cytolysis, ultimately resulting in
necrotic cell death [9-14]. In healthy cells, however, the
cytotoxic N-termini, are normally masked by the autoinhibitory C-termini which prevent the gasdermins from
binding to negatively charged phospholipids, oligomerizing, and forming pores [14,71]. Interestingly, new
evidence also demonstrates that several members including GSDMA-N, GSDMD-N, and GSDME-N can also
form pores in the mitochondria leading to the release of
proapoptotic molecules (Figures 3 and 4) [17].
GSDMD-N pores Induce Pyroptosis and NETosis
Pyroptosis is another form of PCD that plays important roles in pathogen clearance and activation of the
adaptive immune system. In contrast to apoptotic cells,
which maintain their plasma membrane integrity, cells
undergoing pyroptosis are highly inflammatory due to
permeabilization of their plasma membranes and the
consequential release of pro-inflammatory signaling molecules (Figure 1). This form of PCD is initiated in cells
of the innate immune system such as macrophages and
dendritic cells upon sensing a variety of diverse pathogen- and danger-associated molecular patterns (PAMPs
and DAMPs, respectively) such as lipopolysaccharide
(LPS) and ATP. These signals lead to the formation of
multiprotein complexes termed inflammasomes that

recruit the inflammatory caspase pro-caspase-1 either
directly or indirectly through the adaptor protein apoptosis-associated speck-like protein containing CARD
(ASC) leading to its autoproteolytic activation (reviewed
in [72]). Active caspase-1 is a cysteine protease that
cleaves pro-interleukin (IL)-1β and pro-IL-18 to generate
their active signaling forms, IL-1β and IL-18, respectively, which are released from cells undergoing pyroptosis to
activate additional immune responses and inflammation
[73,74]. In addition to canonical inflammasome-driven pyroptosis, a caspase-1-independent inflammasome
called the noncanonical inflammasome can also activate
pyroptosis. The noncanonical inflammasome is activated when intracellular LPS from gram-negative bacteria
binds to the caspase activation and recruitment domain
(CARD) of pro-caspase-11 of mice (or the human orthologs pro-caspase-4 or -5) leading to their oligomerization
and autoactivation [75].
In 2015, using three different techniques (CRISPR/
Cas-9 screening, ENU-forward mouse genetic screening, and high-sensitive quantitative mass spectrometry),
three independent laboratories simultaneously demonstrated that GSDMD is a novel substrate of caspase-1,
-4, and -5 (-11 in mice) that is cleaved between its Nand C-terminal domains downstream of canonical and
noncanonical inflammasome activation and that the
liberated N-terminus harbors intrinsic pyroptotic activity [6-8]. It wasn’t until a year later, however, that six
independent groups then demonstrated mechanistically
that GSDMD-N drives pyroptosis by oligomerizing and
forming pores in the plasma membrane causing the cell
swelling, lysis, and release of cytosolic contents like
IL-1β, IL-18, and high mobility group box 1 (HMGB1)
that characterize pyroptotic cell death (Figure 3) [9-14].
These studies also demonstrated that GSDMD-N binds
specifically to phosphatidylinositol-4-phosphate [PI(4)
P], phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2],
phosphatidylinositol-3,4,5-triphosphate [PI(3,4,5)P3],
phosphatidylserine (PS), and cardiolipin (CL) phospholipids present in biomembranes, a feature that is also
shared with GSDMA-N and GSDME-N [10,14,16,71].
As phosphatidylinositol phosphates and PS are enriched
on the inner leaflet of the plasma membrane, GSDMD-N
only attacks the plasma membrane intracellularly and
not when present extracellularly [10]. Physiologically,
GSDMD-N may play a beneficial role by directly killing
bacteria by forming pores in their cardiolipin-enriched
membranes and by initiating pyroptosis [10,14], however, excessive GSDMD-N-mediated pyroptosis plays
a detrimental role in promoting lethal endotoxemia that
occurs during LPS-induced septic shock [6].
In addition to its role in pyroptosis, GSDMD was
recently shown to play a vital role in NETosis (Table 1).
In response to microbial attack, neutrophils will release
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neutrophil extracellular traps (NETs) composed of DNA
and antimicrobial proteins that trap and kill pathogens, although the mechanism of NET release has remained elusive. However, two groups demonstrated that activation
of GSDMD is required not only for permeabilization of
the plasma membrane that is required for NET extrusion,
but also nuclear membrane permeabilization required for
the release of DNA [76,77].
GSDME-N pores Switch Apoptosis to Secondary
Necrosis
Apoptosis is a noninflammatory and immunologically silent form of PCD as cells maintain their plasma
membrane integrity and do not release proinflammatory
molecules. In addition, upon activation of the apoptotic
pathway, dying cells display cell surface “eat-me” signals, such as PS and calreticulin, that are quickly recognized by neighboring scavenger cells allowing for rapid
phagocytosis through a process called efferocytosis [7880]. In some instances, however, the scavenging capacity of a particular system is inhibited or insufficient to
remove apoptotic cells in a timely manner which causes
these dying cells to progress to secondary necrosis (Table
1; Figure 1). In contrast to apoptosis, secondary necrotic
cells lose their plasma membrane integrity, swell, and
rupture leading to the release of proinflammatory, intracellular molecules including HMGB1 and activated
caspase-3 [81,82]. Interestingly, secondary necrosis has
been thought to be a result of a passive breakdown of the
plasma membrane over time, however recent evidence
suggests that GSDME likely induces secondary necrosis
upon cleavage by caspase-3 during apoptosis. Indeed,
activation of apoptosis by many stimuli including TNFα,
ultraviolet irradiation, etoposide, encephalomyocarditis
virus, and vesicular stomatitis virus infection activates
the apoptotic pathway and caspase-3 leading to cleavage
of GSDME between its N- and C-terminal domains (Figure 4) [15-17]. Like GSDMD, this cleavage liberates the
necrotic N-terminus which over time permeabilizes the
plasma membrane and leads to cellular swelling, cytolysis, and the release of proinflammatory molecules that
characterizes secondary necrosis [15-17]. This function
may contribute to the extensive intestinal tissue damage
and inflammation that occurs in patients undergoing chemotherapy and may be a beneficial target for alleviating
such side effects [16]. Although the role of GSDME in
secondary necrosis downstream of caspase-3 activation
is now well documented, GSDME deficiency may not
prevent secondary necrosis in all cell types [83,84],
suggesting that additional GSDME-independent and celltype specific secondary necrosis mechanisms may play
a dominant role in permeabilizing the plasma membrane
downstream of caspase-3 activation.
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Gasdermins Induce Apoptosis by Permeabilizing
the Mitochondria
New evidence demonstrates that members of the gasdermin family also possess mitochondrial pore-forming
functions. Indeed, downstream of intrinsic and extrinsic
apoptotic activation, caspase-3 generated GSDME-N localizes to the mitochondria and is sufficient to form pores
that release proapoptotic molecules like Cyt c and HtrA2/
Omi [17]. This event creates a positive feedback loop that
promotes caspase-3 activation and further GSDME cleavage and augments the apoptotic program (Figure 4) [17].
This function appears to be conserved in the superfamily
as other members like GSDMA-N and GSDMD-N also
permeabilize the mitochondria to release proapoptotic
factors [17]. Consistent with this idea, previous reports
have demonstrated that GSDMA-N, GSDMD-N, and
GSDME-N all bind to CL and form pores in CL-enriched liposomes [10,14,16,71], a major phospholipid
constituent of the inner mitochondrial membrane that
translocates to the outer mitochondrial membrane during
PCD [85-87]. These findings may also explain previous
observations that these members can activate the apoptotic program, disrupt mitochondrial function, and suppress
tumor growth.
Indeed, GSDMA has been shown to play a role in
activating apoptosis in gastric pit cells. Overexpression
of GSDMA in gastric cancer cell lines is sufficient to
activate caspase-3/-7 as well as induce internucleosomal
DNA cleavage, and physiologically, TGF-β-induced
apoptosis in gastric pit cells is mediated by transcriptional upregulation of GSDMA via recruitment of the
transcription factor LMO1 to the GSDMA promoter [88].
The N-terminus of GSDMA3 can translocate to the mitochondria via Hsp90 where it stimulates the production of
mitochondrial ROS, dissipates mitochondrial membrane
potential, and induces mitochondrial permeability transition (MPT), ultimately leading to cell death [89,90]. In
addition, several mutant mouse lines harboring mutations
in Gsdma3 display alopecia, hyperkeratosis, and skin inflammation due to a depletion of the bulge stem cells that
give rise to hair follicles [91-94], and polymorphisms in
GSDMA have been linked to the development of asthma
[95,96], supporting its role as a pore-forming protein that
promotes both apoptosis and inflammation.
During pyroptosis, GSDMD induces mitochondrial
depolarization in a BAK/BAX-independent manner [97],
and GSDMD-N has recently been shown to localize to
the mitochondria where it causes mitochondrial ROS
generation downstream of Shiga toxin/LPS-induced
canonical and noncanonical inflammasome activation
[98]. Furthermore, several lines of evidence suggest
that activation of the pyroptotic pathway can also lead
to activation of the apoptotic pathway. For example, the
apoptotic caspase-7 is activated downstream of caspase-1
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by a number of inflammasomes including the nod-like
receptor family pyrin domain containing 3 (NLRP3)
inflammasome to induce transcriptional upregulation of
important pro-inflammatory cytokines [99], the nod-like
receptor family CARD containing 4 (NLRC4) inflammasome in order to deliver bacteria to the lysosomal
compartments for degradation [100], and the absent
in melanoma 2 (AIM2) inflammasome [101]. In addition to canonical inflammasome-mediated activation of
apoptotic caspases, the noncanonical inflammasome can
also activate caspases-3/-7 and apoptosis independent
of BID and caspase-1 in vitro and in vivo [102]. How
these pathways are mechanistically linked has remained
unknown, however a recent study demonstrates that
GSDMD-N can form pores in the mitochondria and that
macrophages deficient in GSDMD expression have a
significant delay in caspase-3/-7 activation upon activation of the noncanonical inflammasome [17]. Therefore,
GSDMD-N-mediated MOMP may explain how GSDMD
disrupts mitochondrial function during pyroptosis and
how these apoptotic caspases are activated downstream
of inflammasome activation. It is also interesting to
note, however, that caspase-3/-7 have also been shown
to cleave GSDMD within its N-terminal domain, thus
inactivating its pore-forming functions [15,103]. This
mechanism suggests a potential negative feedback loop
in GSDMD-N-mediated mitochondrial pore-formation,
however future studies should determine the importance
of this regulation.
Furthermore, overexpression of a gain-of-function
mutant of GSDME that causes sensorineural hearing
loss (GSDMEHL) activates apoptosis in HEK293T and
yeast cells [17,104,105], and expression of WT GSDME
sensitizes hepatocellular carcinoma, gastric, melanoma,
thymoma, and acute lymphoblastic leukemia cancer cell
lines to apoptosis [17,106-108]. In addition, GSDME-N
and GSDMEHL colocalize with mitochondria and induce
the production of ROS when expressed in HEK293T and
yeast cells [17,105,109], and gene set enrichment analysis demonstrated that gene sets involved in apoptotic
pathways are downregulated in GSDME-/- mice compared
to GSDME+/+ mice [104] supporting the role of GSDME
as a mitochondrial pore-forming protein that potentiates
apoptotic signaling.
GASDERMINS IN DISEASES AND
DISORDERS
Gasdermins in Cancer
Cancer results from the malignant transformation of
cells that leads to their uncontrolled proliferation and metastasis where they spread and form tumors throughout
the body that disrupt organ function and ultimately lead
to death of the organism. Apoptosis is normally triggered

by many of the changes that a healthy cell must undergo
in order to become tumorigenic including DNA damage
and genomic instability caused by rapid cell division,
hypoxia, oncogene overexpression, and survival factor
depletion. Overtime, however, some cells may continue
accumulating mutations that desensitize them to activation of the apoptotic program and inhibit them from
responding to these triggers, initiating cell death, and
preventing cancer. In fact, evasion of PCD is recognized
as one of the “Hallmarks of Cancer” that most, if not all,
cells must adopt in order to transform and become malignant [110,111]. Mutations that drive cancer can over
activate molecules that inhibit apoptosis (oncogenes) or
inactivate molecules that trigger apoptosis (tumor suppressors).
Interestingly, many members of the gasdermin superfamily are thought to be tumor suppressors. Indeed, GSDMA expression is highly enriched in normal gastric and
esophageal tissue but almost completely lost in a panel
of 14 different gastric cancer cell lines and most primary
esophageal squamous cell carcinomas [88,112,113], and
overexpression of GSDMA in gastric cancer cell lines
decreases colony formation [88]. GSDME also functions
as a tumor suppressor as it is highly downregulated in
breast, gastric, and colorectal cancers due to promoter
hypermethylation [114-121], and its expression positively correlates with superior prognosis and 5-year survival
rates in patients with esophageal squamous cell carcinoma [122] and negatively correlates with an increased
risk of breast cancer metastasis [118]. Furthermore, expression of GSDME in melanoma, acute lymphoblastic
leukemia, gastric, lung, liver, and colon cancer cell lines
leads to decreased cell growth, survival, and colony formation [17,114,119,123,124]. One study also shows that
deletion of GSDME from melanoma cells accelerates
tumor growth and decreases survival outcomes in an in
vivo allograft mouse model [17], however another study
shows no significant difference in tumor growth when
GSDME is deleted from lung cancer cells [125]. This discrepancy may be explained by particular tissue- and/or
cancer-specific drivers that may desensitize lung cancer
cells, but not melanoma cells, to the proapoptotic effects
of GSDME on tumor growth.
GSDMD has also been studied in the context of cancer, however, its function as either a tumor suppressor or
oncogene remains unclear. Support for its role as a tumor
suppressor comes from findings demonstrating that GSDMD is downregulated in primary esophageal squamous
cell carcinomas and gastric cancers although it is normally highly enriched in these tissues and that expression of
GSDMD reduces colony formation and cell proliferation
in gastric cancer cell lines and reduces their ability to form
tumors in xenograft models [113,126]. However, GSDMD was also found to be oncogenic as it is upregulated
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in non-small cell lung cancer (NSCLC) tissue compared
to adjacent, non-cancerous tissue and that knockdown of
its expression in NSCLC cell lines restricts cell growth
in vitro and in vivo [127]. These observations suggest
that the proapoptotic and tumor suppressive functions of
GSDMD may be cancer- and/or tissue-specific.
On the other hand, one superfamily member,
GSDMB, may function as an oncogene as it is amplified
and overexpressed in several gastric cancer cell lines and
primary gastric and breast tumors [113,128,129]. Furthermore, its expression does not limit colony formation in
the same gastric cancer cells that GSDMA and GSDMD
do [113], and its expression in breast cancer promotes invasion and metastasis and decreases patient survival outcomes [130]. Interestingly, GSDMA is highly expressed
in the nondividing, differentiated cells of the esophagus
and stomach while GSDMB is expressed in the rapidly
dividing stem cells of these same organs suggesting that
GSDMB may play a role in promoting cell proliferation
and/or migration, while GSDMA does not [113]. In addition, GSDMB-N does not bind CL like GSDMA-N,
GSDMD-N, and GSDME-N suggesting that it does not
interact with the mitochondria [131]. As all members of
the gasdermin superfamily, except DFNB59, possess the
ability to permeabilize the plasma membrane while there
is only evidence that GSDMA, GSDMD, and GSDME
possess mitochondrial pore-forming activity, it is possible that only the latter function determines whether or not
these members are tumor suppressors.
GSDME Mutations and Hearing Loss
A variety of mutations in GSDME have been reported to cause autosomal dominant, progressive, sensorineural hearing loss (HL) with the age of onset being highly
variable ranging from 0 to 50 years [132-138]. These mutations are found in introns 7 and 8 and include base pair
substitutions and indels that disrupt splice sites and splice
site selection sequences which ultimately lead to skipping of exon 8 during pre-mRNA splicing [135,137,139].
Splicing of exon 7 and 9 introduces a frameshift that
translates amino acids 1-330 followed by an aberrant
stretch of 41 amino acids and a premature stop codon.
As the C-terminus of gasdermin members inhibit their
pore-forming activity, this truncation represents a gainof-function mutation by unmasking the toxic N-terminus.
Supporting this notion, truncating mutations in an Iranian
family in exon 5 that would lead to an inactive N-terminal protein product do not cause HL [140]. Furthermore,
overexpression of GSDMEHL in HEK293T and yeast cells
leads to apoptosis and necrosis [17,104,105], similar to
GSDME-N, and histopathological analysis of inner ear
tissue from patients with GSDME HL mutations revealed
severe degeneration of the cochlea where WT GSDME
is highly expressed [141], indicating that it is a gain-of-
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function mutation. However, as GSDME appears to have
widespread tissue distribution, albeit at varying levels,
it remains to be seen why only the cochlea is affected
and patients harboring these mutations do not present any
obvious additional abnormalities.
One possibility is that expression of the C-terminally
truncated mutant results in a protein that is highly unstable and rapidly degraded by the proteasomal machinery.
Indeed, Wang et al. show that overexpression of GSDMEHL in HeLa cells followed by treatment with cycloheximide resulted in nearly 100 percent degradation within
24 hours whereas little to no loss was observed in cells
expressing WT GSDME or WT GSDME-N [16]. Furthermore, Val Laer et al. generated a mouse model mimicking
the GSDME HL mutation by specifically deleting exon 8
and showed that although the truncated mRNA transcript
is expressed in these mice, no mutant protein could be
detected by immunoblotting [142]. These observations
support the theory that the mutant protein likely has a
short half-life and is degraded before it can cause extensive damage in other organs. This notion, however, still
begs the question of how GSDMEHL specifically damages
the cochlear hair cells to cause HL.
Hair cells are terminally differentiated sensory epithelium that transform physical noises into chemical
signals and transmit them to the brain. These cells must
last the lifetime of mammalian species as they are not regenerated to replace dead or damaged cells. Furthermore,
outer hair cells are extremely sensitive to noise-induced
trauma which can result in the accumulation of ROS,
activation of apoptosis, and cell death [143]. It is therefore possible that hair cells express very low levels of
GSDMEHL that are insufficient to activate apoptosis alone
but instead further increase the sensitivity of these cells
to noise-induced cell death by lowering the threshold for
apoptosis activation. In this case, noise levels that would
normally be insufficient to kill WT hair cells may be sufficient to kill hair cells expressing GSDMEHL, and accumulating exposure to these everyday noises would lead to a
progressive increase in hair cell death, ultimately causing
permanent HL. This theory would also explain the extreme variability in the age of onset and why mutations
cause progressive HL, as the noise levels experienced by
an individual on a daily basis can drastically differ.
CONCLUSIONS AND OUTLOOK
Recent advances in PCD research have greatly deepened our knowledge of gasdermin biology and provided
novel avenues to pursue for therapeutic intervention for
diseases and disorders like sepsis, cancer, and HL. While
these past few years have taught us a lot, there are still
many questions that remain open. GSDMD and GSDME
are activated upon cleavage by the inflammatory caspases
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and caspase-3, respectively, but how are the other gasdermin family members activated? We know that all
members except DFNB59 harbor pore-forming activity
in their N-terminal domains, but how is this activity unleashed from the autoinhibitory C-terminus. Can other
proteases such as granzymes also cleave members of the
gasdermin family, and if so, under what conditions? In
addition, we know that post-translational modifications
(PTMs) like phosphorylation of the N-terminus of GSDME can inhibit oligomerization [17], however, can PTMs
in the C-terminus of these molecules disrupt their autoinhibition and activate their pore-forming activity in the
absence of proteolytic cleavage?
Furthermore, we now know that GSDMD plays important physiological roles in mediating pyroptosis and
controlling pathogen replication, but the physiological
role of GSDME remains unclear. GSDME-/- mice appear to develop normally ruling out the likelihood that
GSDME plays important functions in augmenting the
apoptotic pathways critical for embryonic development,
however, it is activated in response to other stimuli
such as viral infection suggesting that it may function
similar to GSDMD in destroying cellular niches where
microorganisms are hiding and replicating. As GSDME
sensitizes cells to activation of the apoptotic program, it
may significantly limit the spread of pathogens during infection, especially in cells that do not undergo pyroptosis.
Future studies should determine how GSDME-mediated
potentiation of apoptosis contributes to physiological or
pathophysiological processes and if other superfamily
members share similar or redundant functions.
Ultimately, knowledge of gasdermin biology may
provide insight into many clinically useful applications
in treating and preventing disease or alleviating unwanted side effects from toxic chemotherapeutics. Almost all
members of the superfamily possess pro-death activities
by either forming pores in the mitochondria and augmenting apoptosis and/or forming pores in the plasma
membrane and inducing programmed necrosis. As numerous diseases and disorders are a result of dysregulated
programmed cell death pathways, this family of proteins
may reveal themselves as important, novel therapeutic
targets. Indeed, inhibiting GSDME pore-formation may
be useful in reducing intestinal damage and inflammation
caused by chemotherapeutics or in preventing or delaying the onset of HL in patients with GSDME mutations.
Conversely, cancer patients with tumors that have low
GSDME expression may benefit from treatment with a
methyltransferase inhibitor to decrease promoter methylation, restore GSDME expression, and sensitize tumor
cells to apoptosis. Similarly, inhibition of GSDMD may
be useful in preventing sepsis induced by gram negative
bacterial infections. Future studies should also determine
the clinical relevance of the gasdermin family mem-

bers and identify specific inhibitors that prevent their
pore-forming function.
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